Bioprocess Technology Market (2026 - 2033)

Bioprocess Technology Market Summary

The global bioprocess technology market size was valued at USD 25.8 billion in 2025 and is projected to grow from USD 29.6 billion in 2026 to USD 83.5 billion by 2033, at a CAGR of 15.9% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 47.3% in 2025. Market growth is driven by the rising adoption of precision fermentation, along with advancements in bioreactor automation, process monitoring, and scalable fermentation technologies.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

To learn more about this report, Download Free Sample Report

Market Dynamics

The market is experiencing strong growth, driven by rising demand for biopharmaceuticals, advancements in process automation, and increasing adoption of scalable manufacturing technologies. Growing investments in biomanufacturing infrastructure and the development of advanced fermentation and cell culture processes are further supporting market expansion. In addition, the integration of AI, digital process control, and real-time analytics is improving process efficiency, consistency, and productivity, creating new opportunities for market growth.

Market Concentration & Characteristics

The bioprocess technology industry is highly innovative, driven by advancements in process intensification, automated bioreactors, process analytical technology (PAT), and digital process control. Companies are increasingly integrating advanced technologies to improve process monitoring, scalability, and manufacturing consistency. For instance, in August 2023, Sartorius and Repligen launched an integrated system combining the Biostat STR single-use bioreactor with XCell ATF technology, supporting intensified upstream processing and streamlined process control across biopharmaceutical manufacturing applications.

“The market introduction of this integrated bioreactor-intensification system created in partnership with Repligen further reinforces Sartorius’ commitment to being an innovator in process intensification and demonstrates our expertise in upstream processing technologies.”

- Mario Becker, Head of Product Group Bioreactor Technologies, Sartorius

To learn more about this report, Download Free Sample Report

The bioprocess technology industry is experiencing moderate M&A activity, with strategic transactions focused on expanding bioreactor, fermentation, and upstream processing capabilities. Such transactions enable companies to strengthen their technology portfolios and address growing demand for scalable bioprocessing solutions. For instance, in December 2025, Tetra Pak acquired Bioreactors.net, strengthening its bioreactor equipment and fermentation capabilities across laboratory, pilot, and commercial-scale applications.

Regulations have a high impact on the bioprocess technology industry, particularly for systems used in pharmaceutical and biologics manufacturing. Requirements related to GMP, process validation, equipment qualification, contamination control, and data integrity increase the need for validated and standardized technologies. For instance, in January 2025, the FDA issued guidance on the use of AI to support regulatory decision-making for drugs and biological products, establishing a risk-based framework for assessing the credibility of AI models.

The bioprocess technology industry is witnessing high product expansion, with manufacturers broadening their portfolios across laboratory, pilot, and commercial-scale bioprocessing applications. Companies are introducing new equipment and systems with enhanced automation, scalability, and process-control capabilities to address diverse manufacturing requirements.

The bioprocess technology industry is witnessing a moderate to high regional expansion, supported by investments in local biomanufacturing and scale-up infrastructure, particularly across emerging biotechnology hubs. For instance, in February 2026, Glatt and PreferCo established the PreferCo-Glatt Center of Excellence for Bioprocess Scale-Up in Hyderabad, India, featuring bioreactor capacity of up to 1,500 L along with automation, advanced instrumentation, and AI-enabled process intelligence.

Analyst Perspective

The market is expected to grow strongly, driven by the expanding biopharmaceutical pipeline, increasing adoption of biologics and cell & gene therapies, and rising demand for scalable manufacturing processes. Growing emphasis on process efficiency, quality, and cost optimization is accelerating the adoption of single-use systems, process automation, and advanced bioprocessing solutions. Technological advancements and increasing investments in biomanufacturing infrastructure are expected to support long-term market expansion, while market participants focus on automation, workflow integration, and innovative solutions to enhance manufacturing productivity and scalability.

Technology Insights

The downstream bioprocessing segment accounted for the largest revenue share, over 53.2% in 2025, driven by the global adoption of chromatography and other purification technologies for the efficient recovery and purification of biologics, particularly monoclonal antibodies and therapeutic proteins. The segment is further supported by ongoing investments in advanced purification capabilities. For instance, in October 2025, Merck announced an agreement to acquire JSR Life Sciences’ chromatography business to expand its purification solutions for monoclonal antibodies and therapeutic proteins, strengthening downstream bioprocessing capabilities and supporting scalable biopharmaceutical manufacturing.

The upstream bioprocessing segment is expected to register the fastest CAGR over the forecast period, driven by increasing demand for higher-yield cell culture processes, advances in cell-line development and process intensification, and the growing adoption of fed-batch and continuous perfusion technologies for scalable biologics manufacturing. For instance, in March 2026, Sartorius launched a genetically engineered CHO host cell line that delivered up to three-fold higher cell-specific productivity and supported intensified perfusion processes, highlighting continued technological advancement in upstream bioprocessing.

Application Insights

The monoclonal antibodies segment dominated the market with a 40.2% share in 2025, driven by the expanding pipeline of antibody-based therapeutics, increasing demand for targeted treatments, and continued growth in commercial-scale biologics manufacturing. For instance, in March 2024, Lonza announced the acquisition of Roche’s Genentech manufacturing facility in Vacaville, California, for USD 1.2 billion, with plans to invest approximately CHF 500 million to upgrade the facility and enhance capabilities for next-generation mammalian biologics therapies. The facility has approximately 330,000 liters of bioreactor capacity, supporting the growing demand for large-scale biologics manufacturing, including monoclonal antibodies.

The cell & gene therapies segment is expected to register the fastest CAGR over the forecast period, driven by the expanding pipeline of advanced therapies, increasing adoption of personalized and regenerative medicine, and rising demand for specialized bioprocessing solutions capable of handling complex cell and gene therapy manufacturing workflows. Growth is further supported by advancements in viral vector production, cell processing, automation, and scalable manufacturing platforms, which are improving process consistency and supporting the transition of these therapies toward commercial production.

End Use Insights

The biopharmaceutical & pharmaceutical companies segment dominated the market with a share of 37.3% in 2025, driven by the expanding biologics pipeline, increasing in-house manufacturing of complex therapeutics, and continued investments in production capacity and process optimization. The segment’s dominance is further supported by the growing adoption of advanced bioprocessing technologies to improve manufacturing efficiency, product consistency, and scalability across commercial production.

To learn more about this report, Download Free Sample Report

The CROs & CMOs segment is projected to witness the fastest CAGR, driven by the increasing outsourcing of capital-intensive bioprocess development and manufacturing activities, growing demand for specialized technical expertise, and the need for flexible production capacity among emerging biopharmaceutical developers. The shift toward outsourced models is further supported by the growing adoption of integrated services spanning process development, clinical manufacturing, scale-up, and commercial production.

Regional Insights

North America dominated the bioprocess technology market, accounting for the largest revenue share of 47.3% in 2025, supported by strong biomanufacturing capabilities, advanced R&D infrastructure, and investments in domestic production capacity. For instance, in August 2026, the Province of Nova Scotia announced funding to expand the Verschuren Centre’s bioprocessing scale-up facility, which includes a 10,000-L precision fermentation line and is expected to support additional biotechnology companies.

To learn more about this report, Download Free Sample Report

“Innovation is one of Canada’s greatest strengths, and facilities like 10X help turn innovative ideas into real economic opportunities. ACOA’s continued support will help companies develop, test, and scale new technologies right here in Atlantic Canada, strengthening our innovation ecosystem and supporting a more resilient and competitive Canadian economy.”

- Sean Fraser, Minister of Justice and Attorney General of Canada, and Minister responsible for the Atlantic Canada Opportunities Agency

U.S. Bioprocess Technology Market Trends

The bioprocess technology market in the U.S. is expected to grow over the forecast period, supported by increasing investments in advanced biomanufacturing, process automation, and domestic pharmaceutical production. For instance, in August 2026, Genentech completed the structural framework of its approximately USD 2 billion biomanufacturing facility in Holly Springs, North Carolina, which will incorporate automation, robotics, and an AI-powered digital twin to enhance manufacturing efficiency.

Europe Bioprocess Technology Market Trends

The bioprocess technology market in Europe was identified as a lucrative region in this industry, supported by established biotechnology capabilities and increasing policy support for industrial biotechnology and biomanufacturing. For instance, in May 2026, the European Commission launched a consultation on industrial biotechnology and biomanufacturing to support the development of Biotech Act II and improve conditions for investment and scale-up across the region.

The UK bioprocess technology market is supported by a well-established life sciences ecosystem, advanced research capabilities, and growing investments in biopharmaceutical manufacturing. Increasing focus on strengthening domestic production capacity, scaling innovative biological processes, and adopting advanced manufacturing technologies is expected to support demand for bioprocessing systems.

The bioprocess technology market in Germany is anticipated to grow significantly over the forecast period, supported by its strong biotechnology ecosystem and increasing development of large-scale fermentation-based production. For instance, in July 2026, MicroHarvest confirmed the selection of Leuna, Germany, for its first large-scale production plant, designed to produce up to 15,000 tonnes annually through biomass fermentation.

Asia Pacific Bioprocess Technology Market Trends

The bioprocess technology market in the Asia Pacific is expected to grow at the fastest CAGR of 16.4% during the forecast period, supported by expanding biopharmaceutical manufacturing, increasing biotechnology investments, and the development of fermentation and biomanufacturing capabilities. The region’s growing emphasis on local production and process scale-up is expected to increase demand for advanced bioreactors, process-control systems, and other bioprocess technologies.

China bioprocess technology market is expected to experience strong market growth, supported by its large-scale industrial fermentation ecosystem, established biotechnology manufacturing base, and increasing focus on advanced biomanufacturing. The country’s extensive production capabilities for fermentation-derived products provide a strong foundation for adopting scalable, automated bioprocess technologies.

The bioprocess technology market in Japan is expected to grow steadily, supported by its established expertise in fermentation, advanced biotechnology infrastructure, and growing interest in sustainable bio-based manufacturing. The increasing application of fermentation technologies across food, chemicals, and biotechnology is expected to drive demand for sophisticated bioprocessing and scale-up solutions.

Latin America Bioprocess Technology Market Trends

The bioprocess technology market in Latin America is expected to grow gradually, supported by expanding bioprocessing infrastructure, increasing adoption of fermentation technologies, and growing investments in biotechnology and biopharmaceutical manufacturing. Brazil is expected to remain a key regional market, supported by its established fermentation ecosystem and expanding upstream bioprocessing capabilities.

MEA Bioprocess Technology Market Trends

The bioprocess technology market in MEA is expected to grow steadily, supported by increasing biotechnology investments, efforts to develop local biomanufacturing capabilities, and government initiatives promoting biotechnology-led economic diversification. Growing focus on vaccine production, biologics, and industrial biotechnology is expected to create demand for scalable bioprocessing infrastructure across the region.

Key Bioprocess Technology Company Insights

Several well-established companies operate in the market, supported by their portfolios of upstream and downstream bioprocessing systems, bioreactors, filtration, chromatography, and process-control technologies. Leading players such as Thermo Fisher Scientific Inc., Sartorius AG, Merck KGaA, Danaher Corporation, Corning Incorporated, Eppendorf SE, Getinge AB, Repligen Corporation, ABEC, Inc., and PBS Biotech, Inc. maintain a strong market presence through product innovation, technology development, portfolio expansion, and strategic initiatives focused on improving bioprocess efficiency, scalability, automation, and manufacturing consistency.

Key Bioprocess Technology Companies

The following key companies have been profiled for this study on the bioprocess technology market:

• Thermo Fisher Scientific Inc.

• Sartorius AG

• Merck KGaA

• Danaher Corporation

• Corning Incorporated 

• Eppendorf SE

• Getinge AB

• Repligen Corporation

• ABEC, Inc.

• PBS Biotech, Inc.

Recent Developments

• In April 2026, Thermo Fisher Scientific opened its flagship U.S. Bioprocess Design Center in Plainville, Massachusetts, providing advanced bioproduction technologies, technical expertise, training, and collaborative support to accelerate biologics process development, scalability, and delivery of transformative therapies.

"Our new Bioprocess Design Center brings together Thermo Fisher’s experts and customers to tackle some of the most complex challenges in bioprocessing, demonstrating how collaboration and shared innovation can accelerate therapeutic development and help deliver life-changing therapies to patients faster."

- Daniella Cramp, senior vice president and president, BioProduction and Customer Excellence at Thermo Fisher Scientific

• In January 2026, Sartorius expanded its bio-circular product portfolio by introducing certified renewable raw materials into additional single-use bioprocessing technologies, including filters and fluid-management solutions, thereby reducing fossil-based plastics and supporting more sustainable biopharmaceutical manufacturing processes.

• In November 2024, Thermo Fisher Scientific announced plans to establish a bioprocess design center in Hyderabad, India, offering upstream and downstream development, cell-culture media development, single-use manufacturing scale-up, product validation, technical expertise, and training to strengthen regional biopharmaceutical manufacturing capabilities.

• In November 2024, Sartorius Stedim Biotech opened a Center for Bioprocess Innovation in Marlborough, Massachusetts, featuring research laboratories, process development services, customer demonstrations, training, and planned GMP suites to advance bioprocess optimization and manufacturing for next-generation therapeutics.

Global Bioprocess Technology Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global bioprocess technology market report based on technology, application, end use, and region:

To learn more about this report, Download Free Sample Report

• Technology Outlook (Revenue, USD Billion, 2021 - 2033)

  • Upstream Bioprocessing

  • Downstream Bioprocessing

  • Others

• Application Outlook (Revenue, USD Billion, 2021 - 2033)

  • Monoclonal Antibodies

  • Vaccines

  • Recombinant Proteins

  • Cell & Gene Therapies

  • Enzymes

  • Other Biologics

• End Use Outlook (Revenue, USD Billion, 2021 - 2033)

  • Biopharmaceutical & Pharmaceutical Companies

  • CROs & CMOs

  • Academic & Research Institutes

  • Other End Users

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The bioprocess technology market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each bioprocess technology segment quantified using the revenue-capture definitions in the table below.